Prurigo Nodularis Market Size and Share Analysis, Growth Opportunities, Current Treatment Practices, Emerging Therapies, Epidemiology Forecast | Key Companies – Galderma R&D, Incyte Corporation

July 07 12:48 2022
DelveInsight’s “Prurigo Nodularis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Prurigo Nodularis, historical and forecasted epidemiology as well as the Prurigo Nodularis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Prurigo Nodularis Overview: 

Prurigo Nodularis (PN) is an intensely pruritic, chronic skin condition characterized by localized or generalized hyperkeratotic papules and nodules typically in a symmetrical distribution. PN is accompanied by long-standing pruritus and is thought to develop as a reaction to repeated scratching in patients with Chronic Prurigo (CP) from various etiologies, including dermatological, systemic, infectious, and psychiatric. 

PN evolves along with consistent scratching in chronic pruritus conditions and is a subtype of CP. According to the definition by members of the European Academy of Dermatology and Venereology (EADV) Task Force Pruritus group, it is a skin disease due to neuronal sensitization to itch, i.e., amplification of pruritic signaling in the peripheral and central nervous system and development of an itch-scratch cycle. The disease is characterized by hyperkeratotic, crusted or excoriated, light-red to bright-red papules, nodules or plaques with hype pigmented margins as distinguishing features. 

 

DelveInsight has launched a new report on “Prurigo Nodularis Market Insights, Epidemiology, and Market Forecast-2032”. 

 

DelveInsight’s “Prurigo Nodularis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Prurigo Nodularis, historical and forecasted epidemiology as well as the Prurigo Nodularis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. 

 

Some of the key facts of the Prurigo Nodularis Market Report: 

  • The market value of Prurigo Nodularis was valued at USD 676.75 million in 2021 
  • The total diagnosed prevalent population of Prurigo Nodularis in the 7MM was found to be 553,469 in 2021 
  • The United States had the largest share in the total diagnosed prevalent patient population in the 7MM, having a total of 258,998 cases in 2021 
  • According to the studies, females are affected more as compared to males, in the case of Prurigo Nodularis 

 

Request a sample for the Report: https://www.delveinsight.com/sample-request/prurigo-nodularis-market

 

Key benefits of the report:

  1. Prurigo Nodularis market report covers a descriptive overview and comprehensive insight of the Prurigo Nodularis Epidemiology and Prurigo Nodularis  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Prurigo Nodularis market report provides insights on the current and emerging therapies.
  3. Prurigo Nodularis market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Prurigo Nodularis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Prurigo Nodularis market.

 

Prurigo Nodularis Symptoms:

The common symptoms of Prurigo Nodularis include –

  • Itchiness in the skin
  • The skin may burn or sting
  • Development of Itchy bumps in the skin
  • Itchy bumps may vary in color, size, and numbers
  • Dark spots, light spots, or scars can be seen 

 

Prurigo Nodularis Market  

The dynamics of the Prurigo Nodularis market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as INCB054707, Serlopitant, and others during the forecasted period 2019-2032. 

 

Learn more by requesting for sample @Prurigo Nodularis Market Landscape  

 

Prurigo Nodularis Pipeline Therapies: 

  • Nemolizumab
  • INCB054707
  • Serlopitant
  • Vixarelima

 

Prurigo Nodularis Pipeline Key Companies:

  • Galderma R&D
  • Incyte Corporation
  • Vyne Therapeutics 
  • Celldex Therapeutics
  • Kiniksa Pharmaceuticals 

 

Table of Contents 

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Prurigo Nodularis Patient Share (%) Overview at a Glance

5. Prurigo Nodularis Market Overview at a Glance

6. Prurigo Nodularis Disease Background and Overview

7. Prurigo Nodularis Epidemiology and Patient Population

8. Country-Specific Patient Population of Prurigo Nodularis 

9. Prurigo Nodularis Current Treatment and Medical Practices

10. Unmet Needs

11. Prurigo Nodularis Emerging Therapies

12. Prurigo Nodularis Market Outlook

13. Country-Wise Prurigo Nodularis Market Analysis (2018–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Prurigo Nodularis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight 

 

Click here to read more about Prurigo Nodularis Market Outlook 2032

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com

  Categories: